

Breast imaging with an ultra-low field MRI scanner: a pilot study

Authors

Sheng Shen,^{1,2†} Neha Koonjoo,^{1,2†} Friderike K. Longarino,^{3,4,5} Leslie R. Lamb,⁶ Juan C. Villa Camacho,⁶ Torben P.P. Hornung,^{1,3,7} Stephen E. Ogier,^{8,9} Susu Yan,^{2,3} Thomas R. Bortfeld,^{2,3} Mansi A. Saksena,⁶ Kathryn E. Keenan,^{8‡} Matthew S. Rosen^{1,2,10*‡}

Affiliations

¹ A.A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.

² Harvard Medical School, Boston, MA, USA.

³ Department of Radiation Oncology, Radiation Biophysics Division, Massachusetts General Hospital, Boston, MA, USA.

⁴ Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

⁵ Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

⁶ Massachusetts General Hospital, Division of Breast Imaging, Boston, MA, USA.

⁷ Department of Physics, ETH Zürich, Zürich, Switzerland.

⁸ Physical Measurement Laboratory, National Institute of Standards and Technology, Boulder, CO, USA.

⁹ Department of Physics, University of Colorado, Boulder, CO, USA.

¹⁰ Department of Physics, Harvard University, Cambridge, MA, USA.

† These first authors contributed equally to this work. ‡ These senior authors contributed equally to this work.

Corresponding author: Matthew S. Rosen

Email address: msrosen@mgh.harvard.edu

Mailing address: 149 13th Street, Suite 2301, Charlestown MA 02129, USA

Telephone number: +1(617) 643-8636

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83

Abstract

Breast cancer screening is necessary to reduce mortality due to undetected breast cancer. Current methods have limitations, and as a result many women forego regular screening. Magnetic resonance imaging (MRI) can overcome most of these limitations, but access to conventional MRI is not widely available for routine annual screening. Here, we used an MRI scanner operating at ultra-low field (ULF) to image the left breasts of 11 women (mean age, 35 years \pm 13 years) in the prone position. Three breast radiologists reviewed the imaging and were able to discern the breast outline and distinguish fibroglandular tissue (FGT) from intramammary adipose tissue. Additionally, the expert readers agreed on their assessment of the breast tissue pattern including fatty, scattered FGT, heterogeneous FGT, and extreme FGT. This preliminary work demonstrates that ULF breast MRI is feasible and may be a potential option for comfortable, widely deployable, and low-cost breast cancer diagnosis and screening.

MAIN TEXT

Introduction

Approximately 1 in 8 women will develop breast cancer in their lifetime (1), with 85% of cancers occurring in women with no family history of breast cancer (2). Currently mammography is the most used imaging-based tool for breast cancer screening as it is accessible and cost-effective. However, mammography has limitations: it requires ionizing radiation, women find breast compression uncomfortable, and 1-35% of breast cancers are missed on mammograms (3–9). As a result, in 2015, only 65.3% of women over age 40 had undergone a mammogram in the previous 2 years (10).

Currently available MRI-based methods overcome some of these limitations (11), particularly in high-risk groups (12–14). This is because differences in soft tissues can be visualized without obfuscations from dense tissue, and MRI screening has low false-negative rates (15, 16). MRI can detect invasive carcinomas, distinguishing between malignant and benign lesions using T1 weighted imaging with injected contrast agent enhancement (17). Additionally, apparent diffusion coefficient (ADC) can be used to differentiate lesions (18) and assess response to treatment (19). However, traditional clinical MRI operating at 1.5 T and 3 T requires the patient to endure a constricted setting, and currently, MRI as a screening modality is underutilized in high-risk women (defined as a lifetime risk $>20\%$) (20). While fast MRI protocols enable screening in less than 10 minutes (21), the high cost and limited access prohibit their use as a primary screening tool.

Compared to clinical MRI systems operating at 1.5 T or 3 T, ultra-low field (ULF, <10 mT) MRI systems can be significantly less expensive to build and have less stringent installation requirements, allowing increased access. Recently, low-field MRI neuroimaging systems operating at 64 mT have been used in the clinic at the patient bedside for stroke detection (22–24). These systems are safe, do not require an MRI technician, do not require a magnetic- or RF-shielded room, and can be rolled from room to room (25, 26). While operation at lower magnetic field generally leads to images obtained with lower SNR, the effectiveness of low-field MRI for neuroimaging in clinical practice has been demonstrated (22, 24, 27).

84 Based on the recent successes of low field MRI for neuroimaging, we hypothesize that
85 there may be sufficient SNR for whole breast imaging with ULF MRI. NMR-based
86 methods to assess breast cancers began in the early days of MRI with work at 0.71 T to
87 measure T1 and T2 relaxation times of breast tissues (28) Given those promising results,
88 T1 was measured on an entire mastectomy sample (29, 30) and then the whole breast was
89 imaged at 45 mT, which supported the NMR findings, although adoption of the method
90 was limited by an unacceptably long exam duration (31). Other studies report the T1
91 relaxation times of *ex vivo* breast tissues at a range of magnetic fields using NMR
92 dispersion (NMRD) measurements (32, 33). These works found that in the low- and ultra-
93 low field regime the T1 relaxation time of cancerous breast lesions differs from that of
94 healthy fibroglandular and adipose tissues (28, 32, 33). These T1 differences motivate the
95 presently described work; if one could obtain sufficient SNR over a reasonable exam time,
96 ULF breast MRI may be suitable for low-cost breast imaging, retaining the advantages of
97 multi-slice soft tissue imaging compared to the X-ray projection-based method used in
98 mammography.

99 In this study, we describe our preliminary evaluation of breast imaging using ULF MRI.
100 We used an ULF MRI system operating at 6.5 mT and a conical RF coil to image the left
101 breasts of 11 women in the same prone position. ULF MR images of the whole breast
102 revealed essential breast features, including type of fibroglandular tissue, breast outline,
103 nipple areolar complex, and chest wall. These findings are encouraging, and ULF breast
104 MRI may indeed be suitable as a strategy to increase access for comfortable, non-invasive
105 breast imaging.

106




Fig. 1. 6.5 mT ULF MRI scanner configured for breast imaging. (A) Axial view of the ULF MRI scanner. The three axes of the gradient set are shown as Gx (in blue), Gy (in green) and Gz (in magenta), and the biplanar coils of the resistive electromagnet are shown in brown (two per side, four total). The participant lays on the patient table in the prone position with the head turned to the side. The left breast is placed in the RF coil located at the scanner isocenter. (B) CAD model of breast RF coil designed for breast imaging at 276.18 kHz. The dimensions of the RF coil are shown in red.

107




Fig. 2. In vivo experimental setup for breast imaging at ULF. A view of the subject table with red arrow indicating the location of the 3D printed and uniformly wound breast RF coil fixed in the table below the subject. The dimensions of the RF coil are shown in red.

108

109




Fig. 3. Assessment of the imaging volume of the conical-shaped breast RF coil. (A) The magnetic field calculation of the breast RF coil where the color bar indicates the B1 field distribution (in $\mu\text{T/A}$) across the breast volume. (B) A homogeneous phantom was imaged using the setup as shown, with a latex balloon (in blue) filled with deionized water placed inside the breast RF coil. (C) Phantom imaging scan, where a single central slice is extracted from a 21-slice 3D-bSSFP acquisition. The scan shows the signal uniformity of the RF coil. The red line indicates the end of the plate of the RF coil.




Fig. 4. 3D Ultra-low field breast MRI obtained at 6.5 mT from a healthy woman in her 30s with heterogeneous fibroglandular tissue (FGT). 18 out of 21 sequential axial bSSFP-weighted slices of the left breast are shown, and no contrast agent was administered. Data was acquired in approximately 21 minutes with a spatial resolution of $3\text{ mm} \times 3\text{ mm} \times 8\text{ mm}$. All features are visualized in this study: breast outline, FGT, nipple areolar complex, and chest wall. Vertical and horizontal scale bars in white are 3 mm each and are shown in slice 3.




Fig. 5. 3D Ultra-low field breast MRI obtained at 6.5 mT from a healthy woman in her 30s with scattered fibroglandular tissue (FGT). 17 out of 21 representative sequential axial bSSFP-weighted slices of the left breast are shown, and no contrast agent was administered. Data was acquired in approximately 21 minutes with a spatial resolution of $3\text{ mm} \times 3\text{ mm} \times 8\text{ mm}$. The nipple areolar complex and chest wall were not well visualized in this study. The breast outline and FGT are visualized. Vertical and horizontal scale bars in white are 3 mm each and are shown in slice 1.




Fig. 6. 3D Ultra-low field breast MRI obtained at 6.5 mT from a healthy woman in her 30s with extreme fibroglandular tissue (FGT). 18 out of 21 representative sequential axial bSSFP-weighted images of the left breast are represented. No contrast agent was administered. Data was acquired in approximately 21 minutes with a spatial resolution of $3\text{ mm} \times 3\text{ mm} \times 8\text{ mm}$. All features are visualized in this study: breast outline, FGT, nipple areolar complex, and chest wall. Vertical and horizontal scale bars in white are 3 mm each and are shown in slice 1.




Fig. 7. Representative axial bSSFP-weighted slices of the left breast acquired at 6.5 mT from three different subjects. (A) A subject with heterogeneous fibroglandular tissue (FGT) and all features visualized. **(B)** A subject with scattered FGT with the breast outline and FGT visualized. The nipple areolar complex (NAC) and chest wall were not well visualized. **(C)** A subject with extreme FGT and all features visualized. When visible, the indicated features labeled by numbered arrows are breast outline (indicated by 1), NAC (indicated by 2), FGT (indicated by 3), and chest wall (indicated by 4). Vertical and horizontal scale bars in white are 3 mm each and are shown in each slice.

121
122

123 Results

124 Imaging system

125 Imaging was performed on a custom-built electromagnet-based MRI scanner shown in
126 Fig. 1 and modified for breast imaging from its previously described configuration for
127 neuroimaging (34). Figure 2 shows the imaging bed and dedicated RF coil designed to
128 image a single breast. The breast and breast RF coil are placed at the isocenter of the
129 scanner.

130 A close-fitting conical breast coil was designed, and the RF magnetic field generated by
131 this coil was simulated, with the resultant field map depicted in Fig. 3A. Within the breast
132 RF coil, the field homogeneity was quantified, revealing an inhomogeneity of $\pm 60\%$ in the
133 breast volume region and a magnetic field fall-off 3 cm inside the chest wall of 30%. To
134 evaluate the sensitivity of the coil, a homogeneous flexible phantom filled with deionized
135 water was positioned inside the breast RF coil and scanned (Fig. 3B). The phantom
136 imaging result, shown in Fig. 3C, reflects the sensitivity distribution across the RF coil,
137 demonstrating high sensitivity within the coil and a marked decrease in sensitivity towards
138 the opening of the RF coil.

139 Participant characteristics and imaging protocol

140 ULF MRI was used to image the left breast of 11 women (mean age, 35 years \pm 13 years)
141 in this preliminary study. All women completed the study. A 3D balanced SSFP (bSSFP)
142 sequence was used with a voxel size of 3 mm \times 3 mm \times 8 mm. To accelerate the imaging
143 process, an under-sampling factor of 70% was used, and the resulting total scan time was
144 21 minutes 36 seconds. The MR sequence and positioning were well tolerated. None of
145 the images were degraded by patient motion. It is noteworthy that none of the participants
146 experienced discomfort during the exam, and the breast fit naturally in the conical-shaped
147 RF coil without any compression.

148 ULF MRI breast imaging findings

149 Image sets of the entire left breast for three representative subjects are shown in Fig. 4-6.
150 The images in Fig. 7 are single slices of these three representative subjects with the
151 following features labeled by numbered arrows: visibility of the breast outline (indicated
152 by 1), NAC (indicated by 2), FGT (indicated by 3), and chest wall (indicated by 4).
153

154 Breast images from all 11 participants were evaluated by three independent board-certified
155 breast radiologists for the purpose of categorizing breast density and assessing the
156 visibility of essential breast tissues. Individual image scores are reported in Table 1. Breast
157 tissue pattern was assessed using fatty, scattered FGT, heterogeneous FGT, and extreme
158 FGT. Inter-reader reliability of breast tissue pattern was determined using Fleiss' kappa,
159 which resulted in a kappa value of 0.73 (95% confidence interval: 0.72 to 0.74, $p < 0.001$),
160 indicating substantial agreement among the readers.

161 Visibility of the following features in the breast was scored using a 5-point Likert scale (1
162 – not at all visible, to 5 – clearly visible and very sharp): breast outline, fibroglandular
163 tissue (FGT) compared to intramammary adipose tissue, demarcation of the nipple areolar
164 complex (NAC), and the chest wall, defined as visualization of the pectoralis muscle. The
165 limited data set from this pilot study did not allow for proper training of the readers, and
166 given the novelty of the images, the readers were not well “calibrated” to each other. For
167 example, when evaluating the visibility of the breast outline, we find the readers were
168 internally consistent: each reader scores all images with the same visibility (with the

169 exception of a single case for reader 1 that received a higher score). However, each reader
170 has assigned a different visibility score from the other readers. As a result, a binary rating
171 system was adopted from the 5-point scale with a score of 1 remaining not at all visible
172 and scores 2-5 as visible. Fleiss' kappa was also used to measure the agreement regarding
173 the visibility of essential breast tissues. In this binary framework, consensus on the
174 visibility of the breast outline and fibroglandular (FGT) tissue was consistent ($\kappa = 1$),
175 whereas the nipple-areolar complex (NAC) and chest wall exhibited kappa values of 0.54
176 (95% confidence interval: 0.58 to 0.60, $p < 0.001$) and 0.27 (95% confidence interval: 0.26
177 to 0.28, $p < 0.2$), respectively.

178

179 **Table 1: Qualitative assessment of imaging in each of the 11 subjects. Three breast radiologists assessed each imaging feature on a 5-point Likert scale of 1-5 (1 – not at all visible, 2 – barely**
 180 **visible, 3 – clearly visible but blurred, 4 – clearly visible and sharp, 5 – clearly visible and very sharp). Breast tissue pattern (density) was evaluated using F – Fatty, S – Scattered FGT, H –**
 181 **Heterogenous FGT, and E – Extreme FGT.**

Feature	Reader #	Subject #											Statistical Analysis	
		Subj 1	Subj 2	Subj 3	Subj 4	Subj 5	Subj 6	Subj 7	Subj 8	Subj 9	Subj 10	Subj 11	Fleiss Kappa test	
													kappa (95% confidence level)	p-value
Breast tissue pattern	1	S	H	S	H	S	E	H	H	S	H	E	0.73 * (0.72 – 0.74)	<0.001 *
	2	S	H	S	H	S	E	H	H	S	H	E		
	3	F	H	F	S	S	E	H	H	S	H	E		
Breast outline visibility	1	4	4	4	4	5	4	4	4	4	4	4	1	-
	2	3	3	3	3	3	3	3	3	3	3	3		
	3	5	5	5	5	5	5	5	5	5	5	5		
Fibroglandular tissue visibility	1	3	3	3	3	3	3	3	3	3	3	3	1	-
	2	2	3	2	3	2	2	2	3	2	3	3		
	3	3	3	3	3	3	3	3	3	3	3	3		
Nipple Areolar Complex visibility	1	3	4	1	3	1	4	4	3	1	3	3	0.54 (0.58 – 0.6)	<0.001
	2	2	3	1	2	2	3	3	2	1	3	3		
	3	2	4	1	3	2	3	4	3	2	4	4		
Chest wall visibility	1	3	4	4	4	1	4	3	4	4	4	3	0.27 (0.26 – 0.28)	<0.2
	2	1	2	2	2	1	2	2	2	2	2	2		
	3	3	4	4	4	3	3	4	3	4	3	2		

Note.- Subj = Subject

* The Fleiss kappa test on the breast tissue pattern was based on a 4-level score : 1- F, 2- S, 3- S and 4-E.

Inter-reader analysis on the 4 remaining imaging features were assessed on as a binary rating system, where scores of 2 to 5 were categorized as visible and a score of 1 as not visible.

182

183

184

185

Discussion

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

In this preliminary study, we performed MR breast imaging at 6.5 mT on the left breast of healthy participants and were able to identify key breast features, namely breast outline, FGT, NAC, and chest wall. Eleven participants with breasts of various size were included, and images were acquired using a single bSSFP sequence lasting approximately 21 minutes. No external contrast agent was used for these studies. The results presented here encourage us to further develop ULF MRI for breast imaging, including approaches to further reduce exam time.

MRI at the low- and ultra-low magnetic field is challenging due to inherently low Boltzmann polarization and consequently low signal. Two additional consequences of MRI physics at ultra-low magnetic field are relevant to this work. First, as magnetic field decreases, tissue T1 relaxation times generally decrease, while T2 relaxation times are generally constant across fields (32, 35). Second, the magnetic susceptibility artifacts are significantly reduced at ultra-low field. We leverage both of these aspects to our advantage at 6.5 mT, where the efficiency of bSSFP in this regime is maximal (34) and enables banding-free imaging over large fields of view. In this study, the image SNR was sufficient to visualize key breast tissues.

The three expert readers had substantial agreement in their evaluation of breast tissue pattern and most key breast tissues. There were some discrepancies between the readers: specifically, the average scores of Reader 2 were 33% lower than those of Reader 1 (paired t-test, $p < 0.001$) and 28% lower than Reader 3 (paired t-test, $p < 0.001$), whereas the scores of Reader 3 were 7.01% higher than those of Reader 1 (paired t-test, $p < 0.03$). Also, the readers had some disagreement on the visibility of the NAC and chest wall. We attribute this to two factors: lack of training and lack of experience with ULF MRI. The limited data set did not allow for proper training of the readers, and instead only the evaluation criterion were discussed. Additionally, there is a lack of calibration across the readers, given that these are their first experiences with ULF MRI images. Conversely, if these readers were examining clinical breast MRI scans, there would be an implicit calibration, since the readers have all examined many clinical breast MRI scans, over a long period of time (13 years, 3 years and 9 years, respectively).

The NAC and chest wall were not always visible. The absence of NAC on certain scans can be due to either the slice thickness and positioning of the breast or the normal variations in human anatomy, which include flat or inverted nipples. The chest wall was not always visible, primarily in participants with a larger breast. This is a limitation of the coil design. Since the imaging depth of the RF coil is approximately 3 cm from the end plate of the RF coil, the chest wall was not fully captured in participants with larger breast sizes.

Our current methods have some limitations. In addition to the lack of visualization in the chest wall, our preliminary study did not image the axilla, a potential site of breast cancers and nodal disease. Also, the image resolution used here falls short of the clinical requirements for breast cancer screening where a target resolution of $2 \text{ mm} \times 2 \text{ mm} \times 5 \text{ mm}$ is needed to identify small tumors. Ideally, both breasts and axilla could be imaged simultaneously at the target resolution in a scan time of ten minutes or less. To decrease

232 the total exam time, the use of RF coils capable of imaging both breasts simultaneously
233 with a field of view that includes the axilla and chest wall can be developed. Our relatively
234 simple low-cost coil design allows the construction of breast coils in a variety of sizes to
235 maximize the filling factor and thus the SNR for a given subject (36).
236

237 The 6.5 mT ultra-low field magnetic resonance imaging system used here is a
238 configurable test bed system developed in our laboratory to perform preliminary research
239 and refine sequences and techniques for breast cancer imaging. To be considered for
240 clinical use, it is necessary to increase the SNR, as improved SNR can be used to attain
241 increased resolution, decreased scan time, or both. Although the results shown here were
242 acquired at 6.5 mT, operation at even moderately higher magnetic field (B_0) will have a
243 big impact on increasing the attainable resolution and decreasing the scan time for this
244 application. A factor of 3 increase in magnetic field to a nominal 20 mT will result in a
245 factor of 5 increase in SNR, as SNR is proportional to $B_0^{3/2}$ (37). This could allow us to
246 obtain images 25x faster for the same SNR. Further increases in SNR from an increase in
247 field strength to approximately 65 mT (10x higher than the studies presented here) could
248 maintain the mobility and low-cost of a low-field system but with a very significant
249 reduction of imaging time and an increase in spatial resolution.
250

251 We note that the absolute chemical shift between fat and water decreases with decreasing
252 field, making conventional water suppression techniques more challenging. Previous work
253 using NMR and NMR dispersion techniques observe that the T1 of adipose tissue in the
254 breast does not change with field strength, while the T1 of fibroglandular tissues do
255 change with field strength (32, 33). Thus, it may be possible to make a fat suppression
256 technique that takes advantage of the T1 dispersion differences.
257

258 Contrast agents are typically used to increase the contrast between a tissue of interest and
259 the surrounding tissue, and clinical breast MRI requires the use of contrast agents to
260 identify breast tumors (38–40). However, there is concern about the long-term effects of
261 repeated administration of MRI contrast agents such as gadolinium (41). At low magnetic
262 fields, however, gadolinium-based contrast agents do not improve the contrast of the
263 image, in part because gadolinium is not magnetically saturated at low magnetic fields,
264 and thus does not increase the brightness of the image. Recent work highlights the
265 possibilities of iron-oxide nanoparticles and SPIONS for use at low magnetic fields (42,
266 43). A possible benefit of iron-oxide based agents is their biocompatibility, and
267 preliminary in vivo studies used ferumoxytol, an FDA-approved SPION-based treatment
268 of iron deficiency anemia (44, 45). Contrast agents were not used in this preliminary
269 study.
270

271 With this perspective on low-field MRI physics, these initial results encourage us to
272 envision many possibilities for non-contrast, low-field, breast MRI. A purpose-built
273 system could be used in many possible imaging orientations including prone as is current
274 practice, but also extending to supine in the surgical orientation, sitting, or standing.
275 Different magnet designs can be considered to enable portability, low-cost, and integration
276 in a surgical suite or other locations where the magnetic fields of typical clinical systems
277 (1.5 T and 3 T) prohibit safe imaging. ULF MRI systems can increase access, and the
278 absence of gadolinium-based intravenous contrast agents and enclosed spaces may
279 increase use of screening breast MRI.
280

281 In conclusion, we have demonstrated the feasibility of ultra-low field magnetic breast
282 imaging without the use of contrast agents or compression. This approach may provide a
283 new option for breast cancer screening and diagnosis in the future.

284 **Materials and Methods**

285 ***Study Design and Participants***

286 This prospective pilot study was performed from March 2023 to May 2023 and granted
287 institution review board approval from the Office for Human Research Studies (protocol
288 21-579) at the Dana-Farber/Harvard Cancer Center. Written informed consent was
289 obtained from each participant.

291 A total of 11 healthy female participants were enrolled (mean age, 35 years \pm 13 years).
292 Exclusion criteria were: pregnancy, breastfeeding, or inability to undergo MRI due to
293 presence of an implanted or external MRI unsafe device or MR conditional device not
294 meeting the conditions required for the scan. Participants had to be older than 20 and
295 younger than 80 years old. The study also excluded individuals directly supervised by
296 study investigators.

297 ***Imaging System***

298 Imaging was performed on a custom-built electromagnetic MRI scanner, shown in Fig. 1,
299 and previously described (34). The scanner operates at a main field strength of 6.5 mT
300 (Larmor frequency of 276.18 kHz). The shimmed magnetic field inhomogeneity measured
301 over a 20 cm spherical region at isocenter is less than 10 Hz. Imaging gradients are
302 produced by a biplanar gradient set capable of producing linear gradients of up to 1 mT/m
303 in all three axes.

304 For this study, the imaging bed was modified from its previous configuration for
305 neuroimaging (34) to a breast imaging setup where the breast and breast RF coil are
306 located at the isocenter of the scanner. Figure 2 illustrates the imaging bed and dedicated
307 RF coil designed to image a single breast. In order to achieve a good filling factor and thus
308 a high SNR (36), a close-fitting conical breast RF coil was designed. To evaluate RF coil
309 homogeneity, the magnetic field was calculated using the Finite-Element-Method
310 simulation (Ansys Maxwell, 2021, Ansys, Canonsburg, PA, USA). The simulated
311 magnetic field was used to assess the field homogeneity within the breast volume and to
312 determine the magnetic field fall-off beyond the physical end of the coil. The uniformity
313 of the breast imaging region was also assessed using a homogeneous flexible phantom
314 consisting of a latex balloon filled with deionized water. This MR phantom was placed
315 inside the breast RF coil, and as seen in Fig. 3B, it occupied the entire imaging region-of-
316 interest. The imaging protocol used to scan the MR phantom was the same as that of
317 participant scanning protocol.

318 The decision in favor of this type of coil shape was mainly based on promising study
319 results at higher field strengths (46). The conical RF coil was also adapted in size to
320 enable imaging of larger breasts, based on the reported common female breast sizes in the
321 US (47). The coil height is 10 cm; its diameter at the base is 19 cm; and its diameter at the
322 peak is 4 cm (48, 49). The RF coil is uniformly wound on a conical supporting structure.
323 This coil design is capable of imaging the whole breast and the chest wall to a depth of
324 approximately 3 cm. Using this breast coil, the left breast of all participants was imaged
325 with participants in the prone position, as schematically illustrated in Fig. 1A. Photographs
326 of the actual *in vivo* experimental setup can be requested from the corresponding author.
327
328
329
330

MRI acquisition

A 3D balanced SSFP (bSSFP) sequence was used with a flip angle of 70 degrees, TE (echo time)/TR (repetition time) of 13 ms/26 ms, a matrix size of $64 \times 72 \times 21$, 50 averages, and a voxel size of $3 \text{ mm} \times 3 \text{ mm} \times 8 \text{ mm}$. To accelerate the imaging process, an under-sampling factor of 70% was used. The total scan time was 21 minutes 36 seconds. No contrast agents were used. Given the scan duration, the study was limited to imaging one breast, and the left breast was imaged in all participants for consistency.

Images were reconstructed in MATLAB (Natick, MA, USA) using inverse fast Fourier transform (IFFT) with the under-sampled region zero-filled in k-space. Images were converted into DICOM format using the MATLAB function `dicomwrite`.

The MR images of all participants were reviewed by three board-certified breast radiologists (M.A.S., L.R.L and J.C.VC) with 13, 9 and 3 years of experience reading breast MRI. The readers reviewed the evaluation criteria; however, due to the limited data of this pilot study, no additional images were used to train the readers. Images were viewed in DICOM format using 3D Slicer (50). The visibility of the following features in the breast was assessed: visibility of the breast outline, visibility of the fibroglandular tissue (FGT) compared to intramammary adipose tissue, demarcation of the nipple areolar complex (NAC), and visualization of the pectoralis muscle (chest wall). Visibility of these features was assessed using a 5-point Likert scale (1 – not at all visible, 2 – barely visible, 3 – clearly visible but blurred, 4 – clearly visible and sharp, 5 – clearly visible and very sharp). Breast tissue pattern (density) was assessed using four categories: fatty, scattered FGT, heterogeneous FGT, and extreme FGT. Images were also evaluated for motion artifacts.

Statistical Analysis

Inter-reader agreement was assessed by computing Fleiss' kappa among three reader's feature visibility assessments. Due to the novelty of these images, i.e., they were new to all readers, and the limited data set, which did not allow for proper training of the readers, the readers were not "calibrated" to each other, as they are when reading clinical MRI. As a result, the 5-point scale was revised to a binary scale to assess whether or not a feature was visible (1 – not at all visible, 2 or greater – visible). All statistical analyses were performed using IBM SPSS Statistics for Windows, version 26.0. (IBM Corp., Armonk, NY, USA).

References

1. N. Howlader, A. Noone, M. Krapcho, et al., "SEER Cancer Statistics Review, 1975-2017. Table 4.17. Cancer of the female breast (invasive)-Lifetime risk of being diagnosed with cancer given alive and cancer-free at current age." (Bethesda, MD); http://seer.cancer.gov/csr/1975_2017/.
2. G. Haber, N. U. Ahmed, V. Pekovic, Family history of cancer and its association with breast cancer risk perception and repeat mammography. *Am J Public Health* **102**, 2322–2329 (2012).
3. L. R. Lamb, M. Mohallem Fonseca, R. Verma, J. M. Seely, Missed Breast Cancer: Effects of Subconscious Bias and Lesion Characteristics. *RadioGraphics* **40**, 941–960 (2020).

- 380 4. K. Moberg, H. Grundström, S. Törnberg, H. Lundquist, G. Svane, L. Havervall, C. Muren,
381 Two models for radiological reviewing of interval cancers. *J Med Screen* **6**, 35–39 (1999).
- 382 5. S. Ciatto, S. Catarzi, M. P. Lamberini, G. Risso, G. Saguatti, T. Abbattista, F. Martinelli,
383 N. Houssami, Interval breast cancers in screening: The effect of mammography review
384 method on classification. *Breast* **16**, 646–652 (2007).
- 385 6. S. Hofvind, P. Skaane, B. Vitak, H. Wang, S. Thoresen, L. Eriksen, H. Bjørndal, A.
386 Braaten, N. Bjurstam, Influence of review design on percentages of missed interval breast
387 cancers: Retrospective study of interval cancers in a population-based screening program.
388 *Radiology* **237**, 437–443 (2005).
- 389 7. J. A. A. M. Van Dijck, A. L. M. Verbeek, J. H. C. L. Hendriks, R. Holland, The current
390 detectability of breast cancer in a mammographic screening program. A review of the
391 previous mammograms of interval and screen-detected cancers. *Cancer* **72**, 1933–1938
392 (1993).
- 393 8. S. R. Hoff, J. H. Samset, A. L. Abrahamsen, E. Vigeland, O. Klepp, S. Hofvind, Missed
394 and True Interval and Screen-detected Breast Cancers in a Population Based Screening
395 Program. *Acad Radiol* **18**, 454–460 (2011).
- 396 9. National Breast Cancer Coalition, Mammography for Breast Cancer Screening:
397 Harm/Benefit Analysis, *July 2021*. [https://www.stopbreastcancer.org/information-](https://www.stopbreastcancer.org/information-center/positionspolicies/mammography-for-breast-cancer-screening-harm-benefit-analysis/)
398 [center/positionspolicies/mammography-for-breast-cancer-screening-harm-benefit-analysis/](https://www.stopbreastcancer.org/information-center/positionspolicies/mammography-for-breast-cancer-screening-harm-benefit-analysis/).
- 399 10. National Center for Health Statistics, “Health, United States, 2018: Table 33: Use of
400 mammography among women aged 40 and over, by selected characteristics: United States,
401 selected years 1987–2015” (Hyattsville, MD, 2018); <https://www.cdc.gov/nchs/hus.htm>.
- 402 11. R. M. Mann, N. Cho, L. Moy, Breast MRI: State of the Art. *Radiology* **292**, 520–536
403 (2019).
- 404 12. R. M. Mann, C. Balleyguier, P. A. Baltzer, U. Bick, C. Colin, E. Cornford, A. Evans, E.
405 Fallenberg, G. Forrai, M. H. Fuchsjäger, F. J. Gilbert, T. H. Helbich, S. H. Heywang-
406 Köbrunner, J. Camps-Herrero, C. K. Kuhl, L. Martincich, F. Pediconi, P. Panizza, L. J.
407 Pina, R. M. Pijnappel, K. Pinker-Domenig, P. Skaane, F. Sardanelli, with language review
408 by E. D. E. B. C. C. for the European Society of Breast Imaging (EUSOBI), Breast MRI:
409 EUSOBI recommendations for women’s information. *Eur Radiol* **25**, 3669–3678 (2015).
- 410 13. D. Saslow, C. Boetes, W. Burke, S. Harms, M. O. Leach, C. D. Lehman, E. Morris, E.
411 Pisano, M. Schnall, S. Sener, R. A. Smith, E. Warner, M. Yaffe, K. S. Andrews, C. A.
412 Russell, American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct
413 to Mammography. *CA Cancer J Clin* **57**, 75–89 (2007).
- 414 14. D. L. Monticciolo, M. S. Newell, L. Moy, C. S. Lee, S. V. Destounis, Breast Cancer
415 Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the
416 ACR. *Journal of the American College of Radiology*, doi: 10.1016/j.jacr.2023.04.002
417 (2023).
- 418 15. K. Yamaguchi, D. Schacht, G. M. Newstead, A. R. Bradbury, M. S. Verp, O. I. Olopade,
419 H. Abe, Breast Cancer Detected on an Incident (Second or Subsequent) Round of
420 Screening MRI: MRI Features of False-Negative Cases. *American Journal of*
421 *Roentgenology* **201**, 1155–1163 (2013).
- 422 16. S. Vreemann, A. Gubern-Merida, S. Lardenoije, P. Bult, N. Karssemeijer, K. Pinker, R. M.
423 Mann, The frequency of missed breast cancers in women participating in a high-risk MRI
424 screening program. *Breast Cancer Res Treat* **169**, 323–331 (2018).
- 425 17. F. Montemurro, L. Martincich, I. Sarotto, I. Bertotto, R. Ponzzone, L. Cellini, S. Redana, P.
426 Sismondi, M. Aglietta, D. Regge, Relationship between DCE-MRI morphological and
427 functional features and histopathological characteristics of breast cancer. *Eur Radiol* **17**,
428 1490–1497 (2007).

- 429 18. S. L. L. Tan, K. Rahmat, F. I. Rozalli, M. N. Mohd-Shah, Y. F. A. Aziz, C. H. Yip, A.
430 Vijayanathan, K. H. Ng, Differentiation between benign and malignant breast lesions
431 using quantitative diffusion-weighted sequence on 3 T MRI. *Clin Radiol* **69**, 63–71 (2014).
- 432 19. S. C. Partridge, Z. Zhang, D. C. Newitt, J. E. Gibbs, T. L. Chenevert, M. A. Rosen, P. J.
433 Bolan, H. S. Marques, J. Romanoff, L. Cimino, B. N. Joe, H. R. Umphrey, H. Ojeda-
434 Fournier, B. Dogan, K. Oh, H. Abe, J. S. Drukteinis, L. J. Esserman, N. M. Hylton,
435 Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment
436 of Breast Cancer: The ACRIN 6698 Multicenter Trial. *Radiology* **289**, 618–627 (2018).
- 437 20. R. Miles, F. Wan, T. L. Onega, A. Lenderink-Carpenter, E. S. O’Meara, W. Zhu, L. M.
438 Henderson, J. S. Haas, D. A. Hill, A. N. A. Tosteson, K. J. Wernli, J. Alford-Teaster, J. M.
439 Lee, C. D. Lehman, C. I. Lee, Underutilization of Supplemental Magnetic Resonance
440 Imaging Screening Among Patients at High Breast Cancer Risk. *J Womens Health* **27**,
441 748–754 (2018).
- 442 21. C. E. Comstock, C. Gatsonis, G. M. Newstead, B. S. Snyder, I. F. Gareen, J. T. Bergin, H.
443 Rahbar, J. S. Sung, C. Jacobs, J. A. Harvey, M. H. Nicholson, R. C. Ward, J. Holt, A.
444 Prather, K. D. Miller, M. D. Schnall, C. K. Kuhl, Comparison of Abbreviated Breast MRI
445 vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense
446 Breasts Undergoing Screening. *JAMA* **323**, 746–756 (2020).
- 447 22. W. T. Kimberly, A. J. Sorby-Adams, A. G. Webb, E. X. Wu, R. Beekman, R. Bowry, S. J.
448 Schiff, A. de Havenon, F. X. Shen, G. Sze, P. Schaefer, J. E. Iglesias, M. S. Rosen, K. N.
449 Sheth, Brain imaging with portable low-field MRI. *Nature Reviews Bioengineering*, doi:
450 10.1038/s44222-023-00086-w (2023).
- 451 23. M. M. Yuen, A. M. Prabhat, M. H. Mazurek, I. R. Chavva, A. Crawford, B. A. Cahn, R.
452 Beekman, J. A. Kim, K. T. Gobeske, N. H. Petersen, G. J. Falcone, E. J. Gilmore, D. Y.
453 Hwang, A. S. Jasne, H. Amin, R. Sharma, C. Matouk, A. Ward, J. Schindler, L. Sansing,
454 A. de Havenon, A. Aydin, C. Wira, G. Sze, M. S. Rosen, W. T. Kimberly, K. N. Sheth,
455 Portable, low-field magnetic resonance imaging enables highly accessible and dynamic
456 bedside evaluation of ischemic stroke. *Sci Adv* **8**, eabm3952 (2022).
- 457 24. M. H. Mazurek, B. A. Cahn, M. M. Yuen, A. M. Prabhat, I. R. Chavva, J. T. Shah, A. L.
458 Crawford, E. B. Welch, J. Rothberg, L. Sacolick, M. Poole, C. Wira, C. C. Matouk, A.
459 Ward, N. Timario, A. Leasure, R. Beekman, T. J. Peng, J. Witsch, J. P. Antonios, G. J.
460 Falcone, K. T. Gobeske, N. Petersen, J. Schindler, L. Sansing, E. J. Gilmore, D. Y. Hwang,
461 J. A. Kim, A. Malhotra, G. Sze, M. S. Rosen, W. T. Kimberly, K. N. Sheth, Portable,
462 bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage.
463 *Nat Commun* **12**, 5119 (2021).
- 464 25. K. N. Sheth, M. H. Mazurek, M. M. Yuen, B. A. Cahn, J. T. Shah, A. Ward, J. A. Kim, E.
465 J. Gilmore, G. J. Falcone, N. Petersen, K. T. Gobeske, F. Kaddouh, D. Y. Hwang, J.
466 Schindler, L. Sansing, C. Matouk, J. Rothberg, G. Sze, J. Siner, M. S. Rosen, S. Spudich,
467 W. T. Kimberly, Assessment of Brain Injury Using Portable, Low-Field Magnetic
468 Resonance Imaging at the Bedside of Critically Ill Patients. *JAMA Neurol* **78**, 41 (2021).
- 469 26. A. M. Prabhat, A. L. Crawford, M. H. Mazurek, M. M. Yuen, I. R. Chavva, A. Ward, W.
470 V. Hofmann, N. Timario, S. R. Qualls, J. Helland, C. Wira, G. Sze, M. S. Rosen, W. T.
471 Kimberly, K. N. Sheth, Methodology for Low-Field, Portable Magnetic Resonance
472 Neuroimaging at the Bedside. *Front Neurol* **12** (2021).
- 473 27. A. de Havenon, N. R. Parasuram, A. L. Crawford, M. H. Mazurek, I. R. Chavva, V.
474 Yadlapalli, J. E. Iglesias, M. S. Rosen, G. J. Falcone, S. Payabvash, G. Sze, R. Sharma, S.
475 J. Schiff, B. Safdar, C. Wira, W. T. Kimberly, K. N. Sheth, Identification of White Matter
476 Hyperintensities in Routine Emergency Department Visits Using Portable Bedside
477 Magnetic Resonance Imaging. *J Am Heart Assoc* **12** (2023).

- 478 28. D. Medina, C. F. Hazlewood, G. G. Cleveland, D. C. Chang, H. J. Spjut, R. Moyers,
479 Nuclear magnetic resonance studies on human breast dysplasias and neoplasms. *J Natl*
480 *Cancer Inst* **54**, 813–8 (1975).
- 481 29. P. Mansfield, P. G. Morris, R. Ordidge, R. E. Coupland, H. M. Bishop, R. W. Blarney,
482 Carcinoma of the breast imaged by nuclear magnetic resonance (NMR). *Br J Radiol* **52**,
483 242–243 (1979).
- 484 30. P. Mansfield, P. G. Morris, R. J. Ordidge, I. L. Pykett, V. Bangert, R. E. Coupland, R. J. P.
485 Williams, E. R. Andrew, G. K. Radda, Human whole body imaging and detection of breast
486 tumours by n.m.r. *Philosophical Transactions of the Royal Society of London. B,*
487 *Biological Sciences* **289**, 503–510 (1980).
- 488 31. R. J. Ross, J. S. Thompson, K. Kim, R. A. Bailey, Nuclear magnetic resonance imaging
489 and evaluation of human breast tissue: preliminary clinical trials. *Radiology* **143**, 195–205
490 (1982).
- 491 32. S. H. Koenig, R. D. Brown III, Determinants of Proton Relaxation Rates in Tissue. *Magn*
492 *Reson Med* **1**, 437–449 (1984).
- 493 33. V. Bitonto, M. R. Ruggiero, A. Pittaro, I. Castellano, R. Bussone, L. M. Broche, D. J.
494 Lurie, S. Aime, S. Baroni, S. Geninatti Crich, Low-Field NMR Relaxometry for
495 Intraoperative Tumour Margin Assessment in Breast-Conserving Surgery. *Cancers (Basel)*
496 **13** (2021).
- 497 34. M. Sarracanie, C. D. LaPierre, N. Salameh, D. E. J. J. Waddington, T. Witzel, M. S. Rosen,
498 Low-Cost High-Performance MRI. *Sci Rep* **5**, 15177 (2015).
- 499 35. P. A. Bottomley, T. H. Foster, R. E. Argersinger, L. M. Pfeifer, A review of normal tissue
500 hydrogen NMR relaxation times and relaxation mechanisms from 1–100 MHz:
501 Dependence on tissue type, NMR frequency, temperature, species, excision, and age. *Med*
502 *Phys* **11**, 425–448 (1984).
- 503 36. S. Shen, Z. Xu, N. Koonjoo, M. S. Rosen, Optimization of a Close-Fitting Volume RF Coil
504 for Brain Imaging at 6.5 mT Using Linear Programming. *IEEE Trans Biomed Eng* **68**,
505 1106–1114 (2021).
- 506 37. D. I. Hoult, R. E. Richards, The signal-to-noise ratio of the nuclear magnetic resonance
507 experiment. *Journal of Magnetic Resonance (1969)* **24**, 71–85 (1976).
- 508 38. S. H. Heywang-Köbrunner, U. Bick, W. G. Bradley Jr., B. Boné, J. Casselman, A.
509 Coulthard, U. Fischer, M. Müller-Schimpfle, H. Oellinger, R. Patt, J. Teubner, M.
510 Friedrich, G. Newstead, R. Holland, A. Schauer, E. A. Sickles, L. Tabar, J. Waisman, K. D.
511 Wernecke, International investigation of breast MRI: results of a multicentre study (11
512 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519
513 histopathologically correlated lesions. *Eur Radiol* **11**, 531–546 (2001).
- 514 39. S. H. HEYWANG-KÖBRUNNER, R. W. Katzberg, Contrast-Enhanced Magnetic
515 Resonance Imaging of the Breast. *Invest Radiol* **29** (1994).
- 516 40. S. G. Orel, M. D. Schnall, MR Imaging of the Breast for the Detection, Diagnosis, and
517 Staging of Breast Cancer. *Radiology* **220**, 13–30 (2001).
- 518 41. M. Ramalho, J. Ramalho, L. M. Burke, R. C. Semelka, Gadolinium Retention and
519 Toxicity—An Update. *Adv Chronic Kidney Dis* **24**, 138–146 (2017).
- 520 42. S. D. Oberdick, K. V. Jordanova, J. T. Lundstrom, G. Parigi, M. E. Poorman, G. Zabow, K.
521 E. Keenan, Iron oxide nanoparticles as positive T1 contrast agents for low-field magnetic
522 resonance imaging at 64 mT. *Sci Rep* **13**, 11520 (2023).
- 523 43. D. E. J. Waddington, T. Boele, R. Maschmeyer, Z. Kuncic, M. S. Rosen, High-sensitivity
524 in vivo contrast for ultra-low field magnetic resonance imaging using superparamagnetic
525 iron oxide nanoparticles. *Sci Adv* **6**, eabb0998 (2020).
- 526 44. T. C. Arnold, C. W. Freeman, B. Litt, J. M. Stein, Low-field MRI: Clinical promise and
527 challenges. *Journal of Magnetic Resonance Imaging* **57**, 25–44 (2023).

- 528 45. T. C. Arnold, S. By, H. Dyvorne, R. O'Halloran, F. Sayani, L. M. Desiderio, B. Litt, J. M.
529 Stein, "In-vivo ferumoxytol imaging and T1/T2 characterization at 64mT" in *Proceedings*
530 *of the 29th Annual Meeting & Exhibition of the International Society for Magnetic*
531 *Resonance in Medicine (ISMRM)* (Online, 2021), p. program number 1251.
- 532 46. L. Sun, J. O. Olsen, P.-M. L. Robitaille, Design and optimization of a breast coil for
533 magnetic resonance imaging. *Magn Reson Imaging* **11**, 73–80 (1993).
- 534 47. N. Eriksson, G. M. Benton, C. B. Do, A. K. Kiefer, J. L. Mountain, D. A. Hinds, U.
535 Francke, J. Y. Tung, Genetic variants associated with breast size also influence breast
536 cancer risk. *BMC Med Genet* **13**, 53 (2012).
- 537 48. T. P. P. Hornung, N. Koonjoo, Y. Susu, M. S. Rosen, T. R. Bortfeld, "Breast and Chest RF
538 Design and Optimization for Ultra-low Field MRI" in *Proceedings of the 31st Annual*
539 *Meeting & Exhibition of the International Society for Magnetic Resonance in Medicine*
540 *(ISMRM)* (Toronto, Canada, 2023), p. program number 1772.
- 541 49. N. Koonjoo, T. P. P. Hornung, Y. Susu, M. S. Rosen, T. R. Bortfeld, "Low field Breast and
542 Chest Wall Imaging for MR guided Proton Therapy." in *Proceedings of the 31st Annual*
543 *Meeting & Exhibition of the International Society for Magnetic Resonance in Medicine*
544 *(ISMRM)* (Toronto, Canada, 2023), p. program number 3895.
- 545 50. A. Fedorov, R. Beichel, J. Kalpathy-Cramer, J. Finet, J.-C. Fillion-Robin, S. Pujol, C.
546 Bauer, D. Jennings, F. Fennessy, M. Sonka, J. Buatti, S. Aylward, J. V Miller, S. Pieper, R.
547 Kikinis, 3D Slicer as an image computing platform for the Quantitative Imaging Network.
548 *Magn Reson Imaging* **30**, 1323–1341 (2012).
- 549
- 550

551 Acknowledgments

552 The authors would like to thank Darrah Bowden for her invaluable assistance and
553 perspective on the breast imaging configuration. MSR dedicates this work to the memory
554 of Christina Pfeifer Mattig.

555

556 Funding:

557 National Institutes of Health grant 1R21CA267315 (KEK, MSR)
558 Kiyomi and Ed Baird MGH Research Scholar award (MSR)
559 German-American Fulbright Commission (FKL)
560 National Institute of Standards and Technology (KEK, SEO)
561 NIST-PREP 70NANB18H006 from U.S. Department of Commerce (SEO)

562

563 Author contributions:

564 Conceptualization: KEK, MSR
565 Methodology: SS, NK, FKL, MAS, TPPH, SEO
566 Investigation: SS, NK, FKL, MAS, LRL, JVCV, TPPH, MSR
567 Visualization: SS, NK, MAS, JVCV, SEO, KEK, MSR
568 Supervision: SY, TRB, KEK, MAS, MSR
569 Writing—original draft: SS, NK, KEK, MSR
570 Writing—review & editing: SS, NK, FKL, MAS, LRL, JVCV, TPPH, SEO, SY,
571 TRB, KEK, MSR

572

573 **Competing interests:** MSR is a founder and equity holder of Hyperfine, Inc. All other
574 authors declare no conflicts.


575

576 **Data and materials availability:** All data generated or analyzed during the study are
577 available in the main text.


578
579
580
581
582
583

NIST Disclaimer: Certain commercial equipment, instruments, or materials are identified in this paper in order to specify the experimental procedure adequately. Such identification is not intended to imply recommendation or endorsement by NIST, nor is it intended to imply that the materials or equipment identified are necessarily the best available for the purpose.

A Ultra-low field scanner




B



CAD model of breast RF coil


Breast RF coil setup





3D printed breast RF
coil

10 cm


19 cm



A Simulated B1 map




B Phantom imaging setup



Breast RF coil
inserted in patient
table


Balloon
phantom

C bSSFP image



End plate of RF coil


Slice 3




Slice 4




Slice 5



Slice 6




Slice 7




Slice 8




Slice 9



Slice 10



Slice 11



Slice 12



Slice 13



Slice 14



Slice 15




Slice 16



Slice 17



Slice 18




Slice 19




Slice 20



Slice 1



Slice 2



Slice 3



Slice 4



Slice 5



Slice 6



Slice 7



Slice 8



Slice 9



Slice 10



Slice 11



Slice 12



Slice 13




Slice 14




Slice 15




Slice 16




Slice 17




Slice 1




Slice 2




Slice 3




Slice 4




Slice 5




Slice 6




Slice 7




Slice 8



Slice 9




Slice 10



Slice 11



Slice 12



Slice 13



Slice 14



Slice 15



Slice 16



Slice 17



Slice 18



